Background: Interstitial lung disease (ILD) affects 30-70% of patients with Polymyositis (PM) and Dermatomyositis (DM) and is one of the major contributors of morbidity and mortality. Objectives: To study the efficacy and the safety of intravenous cyclophosphamide (IVCYC) according to the Euro-Lupus nephritis protocol for ILD in PM/DM patients. Methods: Twelve patients with PM/DM (mean age 54± SD 8), who received, 500 mg IVCYC every other week, up to 12 times, according to the treating physician, as first line treatment, were retrospectively studied. Six patients had anti-Jo1, 4 anti-PL7, 1 anti-PL12, and 1 anti-MDA5 auto-antibodies. The median (IQR) disease duration before IVCYC was 4 (10,8) months. High doses of prednisolone were given for the first month and then gradually tapered. Response to treatment after a median (IQR) follow-up of 5 (2,8) months was based on pulmonary function tests (PFT) and HRCT). The extent of pure ground-glass opacity (pGGO), pulmonary fibrosis (PF), honeycomb cysts (HCs) and emphysema was scored (0=0%, 1=1-5%, 2=6-15%, 3=16-20%, 4=21-25%, 5=26-50%, 6=51-75%, 7= >75%) in the upper, middle and lower lung zones before and after therapy. The total score for each finding was calculated as the sum of the scores of the 3 zones (1). Results: The mean IVCYC total amount was 4.75 ± SD 1.4 gr. Before IVCYC, the median (IQR) values of forced vital capacity (FVC)%, forced expiratory volume in 1 second (FEV1)%, vital capacity (VC)%, total lung capacity (TLC)% and diffusion capacity of the lung for carbon monoxide (DLCO)% were 67 (26), 60 (14), 63 (11), 63 (12) and 57 (25), respectively. After therapy, the median (IQR) values became 74 (29), 80 (18), 80 (24), 77 (19) and 68 (27), respectively. The difference between baseline and follow-up TLC%, FVC% ( fig.1 ) and VC% median values was statistically significant (p<0,05). FVC% and TLC% improved >10% in 6 and 5 patients, respectively; DLCO% improved >15% in 3 patients. Before IVCYC, the median (IQR) scores of pGGO and PF were 12,5 (9) and 12 (7), respectively. After IVCYC, they decreased (7 (6) and 9 (12), respectively). In the group of anti-Jo-1 positive patients, the difference was close to the statistically significant (from 13,5 (10) to 7,5 (15), p=0,06 and from 9,5 (10) to 4,5 (16), p=0,07, respectively). The median (IQR) pGCO scores of anti-Jo-1 negative patients improved (from 11,5 (11) to 8,50 (17)), while the median (IQR) PF scores were unchanged (from 13,5 (4) to 14 (10)). At baseline and follow up, the median scores of HCs and emphysema were 0. No statistically significant correlations were found between PFT values and HRCT scores. The difference of PF extent was negatively correlated with the disease duration before the first IVCYC (r=-0,56, p=0,056, fig  1) . No adverse events or drug toxicity were observed. Conclusions: After IVCYC according to the Euro-Lupus nephritis protocol PFT and HRCT findings improved in PM/DM patients with ILD without any adverse events or drug toxicity. Longitudinal controlled studies are needed to confirm the efficacy and the safety of this treatment protocol. 
SAT0330 LOWER PREVALENCE BUT COMPARABLE CLINICAL CHARACTERISTICS AND PROGNOSIS OF SYSTEMIC SCLEROSIS IN CRETE-GREECE AS COMPARED TO OTHER EUROPEAN COUNTRIES: A SINGLE CENTER EXPERIENCE
A. Repa, I. Gergianaki, G. Spyrou, N. Kougkas, A. Kountouri, N. Avgoustidis, G. Bertsias, P. Sidiropoulos. Rheumatology, University of Crete, Heraklion Crete, Greece Background: Systemic Sclerosis (SSc) is a rare, multisystemic connective tissue disease with significant morbidity. Prevalence and incidence of SSc varies worldwide (0.7-265 cases per 100,000/y 1,2 and 0.06-12.2 cases per 100,000/y 1 respectively). Mortality in SSc patients remains 3.5 times higher than the general population 3 . We sought to generate updated data on the epidemiology and burden of SSc in the Greek population. Objectives: To study the prevalence and incidence of SSc, describe the clinical characteristics and assess mortality and main causes of death in Crete (Greece) over a 5-year period (2010) (2011) (2012) (2013) (2014) (2015) . Methods: We conducted a cohort Study in defined geographic area (6,5% of Greek population). We reviewed demographics, clinical features, autoantibodies status and the causes of death from the Scleroderma cohort followed at the Rheumatology clinic of the University Hospital, Heraklion. The cause of death was categorized as related or not to scleroderma. Incidence and prevalence were estimated including patients living permanently in Crete who fulfilled SSc 2013 ACR/EULAR Classification Criteria for Scleroderma. Results: 72 patients (88% women, mean±SD age at diagnosis 48.5±16.7 years [range 15-87]) were identified, corresponding to a crude point prevalence of 13.8/10 5 (CI 95% 11-17/10 5 ) (December 2015). The Incidence rate was estimated at 0.05/10 5 per year (period 2010-2015) . Diffuse SSc (dSSc) was present in 27.7%, limited SSc (lSSc) in 72.2%, while an overlap syndrome in 19.4% (9.7% with systemic lupus erythematosus). Frequencies of anti-Scl70 and anti-cectromere antibodies were 59.7% and 9.7%, respectively. Arthritis was present in 69.5%, lung involvement in 61% (9.7% pulmonary arterial hypertension [PAH] ), whereas only a single patient developed renal crisis. 8.3% developed cancer. Case fatality rate during 2010-2015 was 9.7% (CI 95% 7.4-11.9) with an average (±SD) age of death at 65.2 (± 17.6) years. Mortality cases were related to SSc in 30.7%. The main cause of death was sepsis (30.8%) followed by PAH and cardiac arrest (15.4% each). Male gender (p<0.001) and presence of PAH (p=0.001) were related to mortality. Mean disease duration until death was 5.3
